WordType Designs
Driven To Distractions©
The Sound of One Hand Clapping©


A rchive Date
[ 10-09-2020 ]
Category
[ International Relations ]
sub-Categoy
[ India ]

      [https://www.cbc.ca/news/world/coronavirus-covid19-world-sept-10-1.5718428

      Coronavirus: What's happening around the world on Thursday
      UN calls for $35 billion US in funding to support vaccine acceleration program
      The Associated Press · Posted: Sep 10, 2020 6:56 AM ET

      United Nations Secretary General Antonio Guterres called for $35 billion US ($46 billion Cdn) more - including $15 billion ($19.7 billion Cdn) in the next three months - for the World Health Organization's program to back vaccines, treatments and diagnostics against COVID-19.

      Some $3 billion has been contributed so far, Guterres told an online event on Thursday, calling it "seed funding" that was less than 10 per cent of what the WHO wants for the program, formally called Access to COVID-19 Tools (ACT) Accelerator.

      Financial support has, so far, lagged goals, as countries or governments including the European Union, United Kingdom, Japan and the United States reach bilateral deals for vaccines, prompting Guterres and WHO General Director Tedros Adhanom Ghebreyesus to plead with countries to contribute.

      "We now need $35 billion more to go from 'start up' to 'scale up and impact,'" Guterres said at a meeting of a council formed to help the ACT Accelerator gain traction. "There is real urgency in these numbers. Without an infusion of $15 billion over the next three months, beginning immediately, we will lose the window of opportunity."

      The total sought, $38 billion  ($46 billion Cdn), is more than the previously published $31.3 billion ($41.1 billion Cdn) ACT goal and includes for the first time additional funding for health systems, in addition to vaccines, therapeutics and diagnostics, a WHO spokeswoman said.

      European Commission President Ursula von der Leyen pledged backing, having in August already promised 400 million euros ($624 million Cdn) to the COVAX vaccine portion of the program.

      "It is difficult to find a more compelling investment case. The European Commission will remain deeply and entirely committed to the success of the ACT Accelerator," von der Leyen said. "The world needs it, we all need it."

      Tedros renewed calls for scaling up COVID-19 clinical trials. AstraZeneca this week suspended late-stage trials on its potential vaccine after an illness in a participant in Britain. AstraZeneca CEO Pascal Soriot said on Thursday if safety reviewers allow a restart, the company should still know by year's end if its vaccine works.

      AstraZeneca's pause is a "wake-up call" but should not discourage researchers, WHO's chief scientist said Tuesday.

      "This is a wake-up call to recognize that there are ups and downs in clinical development and that we have to be prepared," Soumya Swaminathan told a virtual briefing from Geneva.

      "We do not have to be discouraged. These things happen."

      Governments are desperate for a vaccine to help end the COVID-19 pandemic, which has caused more than 900,000 deaths and global economic turmoil, and the WHO had flagged AstraZeneca's, being developed with Oxford University, as the most promising.

      However, the drugmaker suspended late-stage trials on its potential vaccine this week after a participant in Britain was reported to be suffering from symptoms associated with a rare spinal inflammatory disorder.

      "It's a race against this virus, and it's a race to save lives. It's not a race between companies, and it's not a race between countries," said Mike Ryan, WHO's head of emergencies.

      ©2020 CBC/Radio-Canada. All rights reserved


      World Fact Book (CIA)]


Some pages may require Adobe Acrobat Reader



Copyright and Fair Use Information: The contents of this web site is protected by international copyright laws and may not be reproduced in any form or manner whatsoever, if for the purpose of resale or solicitation of a donation. The essays included here, may be reproduced only if: 1)They are not altered in any way; 2) reproductions must be accompanied by this copyright page ; and 3) it is given freely and without charge.
Fair use: The fair use of copyrighted work, including such use by reproduction in copies or phonorecords or by any other means specified in above sections, for purposes such as criticism, comment, news reporting, teaching (including multiple copies for classroom use), scholarship, or research, is not an infringement of copyright. In determining whether the use made of a work in any particular case is fair use the factors to be considered include : (1) the purpose and character of the use, including whether the use is of a commercial nature or is for nonprofit educational purposes; (2) the nature of the copyrighted work; (3) the amount and substantiality of the portion used in relation to the copyrighted work as a whole, and; (4) the effect of the use upon the potential market value of the copyrighted work.

Home | About Narrative? |Contact
Copyright © 2025. All Rights Reserved
HAG122125 (1998 -2026)